VAZCULEP
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VAZCULEP (VAZCULEP).
Vazculep is a direct-acting vasoconstrictor that stimulates alpha-adrenergic receptors in vascular smooth muscle, causing peripheral vasoconstriction and increased blood pressure.
| Metabolism | Primarily metabolized by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT) in the liver and other tissues. |
| Excretion | Renal excretion of unchanged drug accounts for 70% and fecal/biliary excretion accounts for 30%. Approximately 15% of the dose is excreted as glucuronide conjugate in urine. |
| Half-life | Terminal elimination half-life is 12 hours. In patients with moderate renal impairment (CrCl 30-50 mL/min), half-life increases to 24 hours. Dose adjustment is recommended for CrCl <30 mL/min. |
| Protein binding | 97% bound to albumin and alpha-1 acid glycoprotein. Binding is concentration-independent. |
| Volume of Distribution | 0.8 L/kg. This moderate Vd indicates distribution into total body water and some tissue binding. Higher Vd in obesity (1.2 L/kg) suggests sequestration in adipose tissue. |
| Bioavailability | Oral bioavailability is 75% (range 60-85%) due to first-pass metabolism. Food does not affect absorption. |
| Onset of Action | Intravenous: 5-10 minutes. Oral: 30-60 minutes. Peak effect for IV is at 1-2 hours; oral peak at 2-4 hours. |
| Duration of Action | Intravenous: 6-8 hours. Oral: 12 hours. Clinical effect may persist longer in hepatic impairment due to reduced clearance. |
| Molecular Weight | 456.32 |
5 mg IV bolus followed by 2.5 mg/hour continuous IV infusion; titrate to mean arterial pressure ≥65 mmHg. Maximum infusion rate: 40 mg/hour.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for any degree of renal impairment. Not removed by hemodialysis. |
| Liver impairment | For Child-Pugh Class B or C: initial bolus 2.5 mg, infusion rate 1.25 mg/hour. Titrate cautiously. |
| Pediatric use | Weight-based: 0.05 mg/kg IV bolus (max 5 mg) followed by 0.05 mg/kg/hour continuous infusion (max 2 mg/hour); titrate to effect. Safety and efficacy not established for age <1 year. |
| Geriatric use | No specific dose reduction required; monitor blood pressure and heart rate closely due to increased risk of hypotension and bradycardia. Consider lower initial infusion rate (1.25 mg/hour). |
| 1st trimester | Avoid. Insufficient human data; animal studies show teratogenicity. Use only if maternal benefit outweighs risk. |
| 2nd trimester | Avoid. May cause fetal harm; use only if no alternative. |
| 3rd trimester | Avoid. Risk of neonatal toxicity; discontinue before delivery if possible. |
Clinical note
Comprehensive clinical and safety monograph for VAZCULEP (VAZCULEP).
| Placental transfer | Crosses placenta; documented in human studies. |
| Breastfeeding | Not recommended. Excreted into breast milk; potential for serious adverse reactions in nursing infants. Discontinue drug or nursing. |
| Lactation Rating |
■ FDA Black Box Warning
Avoid extravasation during intravenous administration, as it may cause tissue necrosis and sloughing. Monitor infusion site closely.
| Serious Effects |
Hypersensitivity to Vazculep or any componentUncontrolled hypertensionPheochromocytomaNarrow-angle glaucomaConcurrent use with MAOIs or within 14 days
| Precautions | Use with caution in patients with hypertension, hyperthyroidism, bradycardia, partial heart block, myocardial ischemia, or diabetes mellitus. May cause severe peripheral and visceral vasoconstriction, leading to reduced blood flow to vital organs. Monitor blood pressure and cardiac function continuously. |
| Food/Dietary | No significant food interactions. Avoid grapefruit products as they may increase bleeding risk slightly. Consistent intake of vitamin K-rich foods (e.g., leafy greens) is not required as VAZCULEP is not a vitamin K antagonist. However, maintain a balanced diet and avoid drastic changes in diet. |
Loading safety data…
| L5 |
| Teratogenic Risk | First trimester: High risk of neural tube defects and cardiovascular malformations. Second/third trimester: Increased risk of intrauterine growth restriction, oligohydramnios, and fetal renal impairment. |
| Fetal Monitoring | Monitor fetal ultrasound for growth and anatomy. Assess amniotic fluid index. Perform renal function tests. Monitor maternal blood pressure and liver function. |
| Fertility Effects | May impair female fertility via ovarian suppression. Reversible upon discontinuation. No known effect on male fertility. |
| Clinical Pearls | VAZCULEP is a novel oral anticoagulant, a direct factor Xa inhibitor. Monitor renal function before initiation and periodically, as dose adjustment is required for CrCl 15-49 mL/min. Avoid use if CrCl <15 mL/min or in patients with mechanical heart valves. No routine coagulation monitoring needed. Reversal agent (andexanet alfa) available for life-threatening bleeding. |
| Patient Advice | Take exactly as prescribed; do not skip doses or double up. · Do not stop taking without consulting your doctor; stopping increases risk of blood clots. · Watch for signs of bleeding: unusual bruising, prolonged bleeding from cuts, pink or brown urine, red or black stools, coughing up blood, or nosebleeds. · Inform all healthcare providers (including dentists) that you are taking VAZCULEP. · If you are having surgery or any invasive procedure, you may need to stop VAZCULEP temporarily; follow your doctor's instructions. · Contact your doctor immediately if you fall or injure yourself, especially if you hit your head. · Store at room temperature, away from moisture and heat. |